Cargando…
Determination of Plasma Heparin Level Improves Identification of Systemic Mast Cell Activation Disease
Diagnosis of mast cell activation disease (MCAD), i.e. systemic mastocytosis (SM) and idiopathic systemic mast cell activation syndrome (MCAS), usually requires demonstration of increased mast cell (MC) mediator release. Since only a few MC mediators are currently established as biomarkers of MCAD,...
Autores principales: | Vysniauskaite, Milda, Hertfelder, Hans-Jörg, Oldenburg, Johannes, Dreßen, Peter, Brettner, Stefan, Homann, Jürgen, Molderings, Gerhard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4409380/ https://www.ncbi.nlm.nih.gov/pubmed/25909362 http://dx.doi.org/10.1371/journal.pone.0124912 |
Ejemplares similares
-
Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis
por: Seidel, Holger, et al.
Publicado: (2021) -
Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options
por: Molderings, Gerhard J, et al.
Publicado: (2011) -
Case Report: Treatment of systemic mastocytosis with sunitinib
por: Molderings, Gerhard J., et al.
Publicado: (2017) -
Prostaglandin D(2)-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study
por: Schäfer, Dirk, et al.
Publicado: (2014) -
Pharmacological treatment options for mast cell activation disease
por: Molderings, Gerhard J., et al.
Publicado: (2016)